Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow creating humanized antibodies that can be used either alone in unlabeled or naked form or conjugated with radioactive isotopes, chemotherapeutics, cytokines, or toxins.